172 Results

People

  1. Motzer
    Motzer
  2. Abrey
    Abrey
  3. De Angelis
    De Angelis
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Kelly
    Kelly
  7. Scher
    Scher
  8. Drilon
    Drilon
  9. Feldman
    Feldman
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)
  7. Biostatistics Service (27)
  8. Thoracic Oncology (19)
  9. Division of Subspecialty Medicine (18)
  10. GSK Faculty (18)
  1. "hypophosphatemia"
Formats
  1. Journal Article (160)
  2. Review (7)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)

More Groups

People
  1. Robert Motzer (18)
  2. Lauren Abrey (9)
  3. Lisa De Angelis (8)
  4. Gregory Riely (7)
  5. Ghassan Abou-Alfa (6)
  6. Howard Scher (6)

More People

Years
  1. 2025 (8)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (21)

More Years

Publications
  1. Lancet Oncology (16)
  2. Cancer (11)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (10)
  5. New England Journal of Medicine (10)
  6. Neuro-Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (25)
  2. Elsevier Inc. (19)
  3. American Association for Cancer Research (12)
  4. Wiley Blackwell (12)
  5. Oxford University Press (11)
  6. Springer (11)

More Publishers

Results (172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL
    Journal Article

    Hochhaus, A.; Réa, D.; Boquimpani, C.; Minami, Y.; Cortes, J. E.; Hughes, T. P.; Apperley, J. F.; Lomaia, E.; Voloshin, S.; Turkina, A.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma
    Journal Article

    Chintala, N. K.; Choe, J. K.; McGee, E.; Bellis, R.; Saini, J. K.; Banerjee, S.; Moreira, A. L.; Zauderer, M. G.; Adusumilli, P. S.; Rusch, V. W.
    Frontiers in Immunology (2023)

    Fulltext@MSK | Save
  • Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
    Review

    Yang, J. C. H.; Zhou, C.; Jänne, P. A.; Ramalingam, S. S.; Kim, T. M.; Riely, G. J.; Spira, A. I.; Piotrowska, Z.; Mekhail, T.; Garcia Campelo, M. R.; more...
    Expert Review of Anticancer Therapy (2023)

    Fulltext@MSK | Save
  • Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation
    Review

    Sermer, D.; Elavalakanar, P.; Abramson, J. S.; Palomba, M. L.; Salles, G.; Arnason, J.
    Blood Reviews (2023)

    Fulltext@MSK | Save
  • Pilot trial of homebound hematopoietic cell transplantation
    Journal Article

    Landau, H. J.; Orlando, E.; Rodriguez, E. S.; Applebaum, A.; Mitchell, H. R.; Peled, J. U.; Khan, N.; Funnell, T.; Chung, D.; Scordo, M.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia
    Journal Article

    Prebet, T.; Goldberg, A. D.; Jurcic, J. G.; Khaled, S.; Dail, M.; Feng, Y.; Green, C.; Li, C.; Ma, C.; Medeiros, B. C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: A case for response-adapted approach
    Journal Article

    Lahoud, O. B.; Landau, H.; Nguyen, J.; Devlin, S.; Lendvai, N.; Weltz, J.; Ayorinde, T.; Chung, D. J.; Lesokhin, A. M.; Kewalramani, T.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Triplet therapy, transplantation, and maintenance until progression in myeloma
    Journal Article

    Richardson, P. G.; Jacobus, S. J.; Weller, E. A.; Hassoun, H.; Lonial, S.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Voorhees, P. M.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study
    Journal Article

    Zauderer, M. G.; Szlosarek, P. W.; Le Moulec, S.; Popat, S.; Taylor, P.; Planchard, D.; Scherpereel, A.; Koczywas, M.; Forster, M.; Cameron, R. B.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
    Journal Article

    Choudhury, A. D.; Higano, C. S.; de Bono, J. S.; Cook, N.; Rathkopf, D. E.; Wisinski, K. B.; Martin-Liberal, J.; Linch, M.; Heath, E. I.; Baird, R. D.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save